SCP Foundation Secure, Contain, Protect About About Us Site Rules FAQ Licensing Criticism Policy Article Deletions Community Site News IRC Chat Authors' Pages Artist Directory Contest Archive Staff List Resources Guides Essays & Resources Wiki Syntax Sandbox Usertools Sister Sites SCP International Wanderer's Library Contact Us ≡ About About Us Site Rules FAQ Licensing Criticism Policy Article Deletions Contact Staff Community Site News IRC Chat Authors' Pages Artist Directory Contest Archive Staff List Resources Guides Search this site Search • ◦ ◦ ◦ ◦ ◦ ◦ • ◦ ◦ ◦ ◦ ◦ ◦ • ◦ ◦ ◦ ◦ ◦ • ◦ ◦ • • ◦ ◦ ◦ ◦ ◦ ◦ ◦ • ◦ ◦ ◦ ◦ ◦ ◦ • ◦ Essays & Resources Wiki Syntax Sandbox Usertools Sister Sites SCP International Wanderer's Library Create account or Sign in Getting Started Guide for Newcomers Join the Site Contribute | FAQ Universe Hub Main | Forum SCP by Series I | II | III | IV | V VI | VII | VIII | IX Other SCP Explained | Joke International Feed New Pages Shortest | Top Rated Recent Changes New Forum Posts Lowest Rated Pages Stories Tales Hub | Series Groups of Interest GoI Formats Canon Hub Discovery Artwork Hub Curated Lists Curated Tale Series Tag Search Random SCP | Tale | GOI | Art Random Page ◦ ◦ ◦ ◦ • ◦ ◦ SCP-6763 + CODE /* BLANKSTYLE CSS [2021 Wikidot Theme] By Placeholder McD and HarryBlank Based on: Paperstack Theme by EstrellaYoshte Penumbra Theme by EstrellaYoshte */ @import url('https://fonts.googleapis.com/css2?family=Montserrat:ital,wght #page-content { font-size: .9rem; } #main-content { top: -1.6rem; padding: 0.2em; } div#container-wrap { background-image: none; } div#header { background-image: none; } #header h1, #header h2 { margin-left: 0; float: none; text-align: center; #header h2 { margin-top: 0.5rem; } #header h1 span, #header h2 span { font-size: 0; display: none;} #header h1 a::before, #header h2::before { color: #000; letter-spacing: 1px; font-family: 'Montserrat', sans-serif !important; text-shadow: none; } #header h1 a::before { content: var(--header-title, "R\0026 C SITE-43"); font-weight: 400; font-size: 1.3em; } #header h2::before { content: var(--header-subtitle, "SUBVERTING COMMON PRACTICE"); font-weight: 700; font-size: 1.2em; } @media (max-width: 707px) { #header h1 a::before { font-size: 1.6em; } } #login-status, #login-status a { color: #333333; } #page-title { display: none; } #footer, #footer a { background: transparent; color: #333333; } #search-top-box-input, #search-top-box-input:hover, #search-top-box-input:focus, #search-top-box-form input[type=submit], #search-top-box-form input[type=submit]:hover, #search-top-box-form input[type=submit]:focus { border: none; background: #333333; box-shadow: none; border-radius: 0px; color: #efefef; } #search-top-box input.empty { color: #999999; } #search-top-box { top: 2.3rem!important; right: 8px; } #top-bar { display: flex; justify-content: center; right: 0; top: 7.9rem; } #top-bar, #top-bar a { color: #333333; } h1, h2, h3, h4, h5, h6 { font-family: 'Montserrat', sans-serif; color: #000; letter-spacing: 1px; } h1 { font-size: 2em; } h2 { font-size: 1.45em; } div#extra-div-1 { height: 160px; width: 100%; top: 0; position: absolute; background: url('https://scp-wiki.wdfiles.com/local--files/theme%3Abla background-size: contain; background-repeat: no-repeat; background-position: 50% 50%; z-index: -1; } @media (max-width: 707px) { div#extra-div-1 { top: 15px; } } body { background-image: linear-gradient( to bottom, #e0e0e0, #e0e0e0 90px, #e0e0e0 90px, #ffffff 200px, #ffffff 200px, #ffffff 100%); background-repeat: no-repeat; } :root { --timeScale: 1.5; --timeDelay: 1.5s; --posX: calc(50% - 358px - 13rem); --fnLinger: 1s; } #page-content hr { background-color: #000; } #page-content tr th { padding: 6px; border: #000 1px solid; } #page-content tr td { padding: 12px; border: #000 1px solid; line-height: 1.4; } #page-content .sidebox tr td, #page-content .sidebox tr th { padding: 0.35em; } #side-bar { border-right: 1px solid #333; background: #DDD; } #side-bar .side-block { border: 1px solid #333; border-radius: 0; box-shadow: none; } #top-bar div.open-menu a { border: 1px solid #333; border-radius: 0; box-shadow: none; } @media (max-width: 767px) { #side-bar:target { border: 1px black; box-shadow: none; } } #side-bar .side-block { border: 1px solid #333; border-radius: 0; box-shadow: none; background-color: #FDF6D7; } #side-bar .side-block.media { background-color:#D7EFE7; } #side-bar .side-block.resources { background-color:#F5D8E0; } #page-content .creditRate{ margin: unset; margin-bottom: 4px; } #page-content .rate-box-with-credit-button { background-color: #ffffff; border: solid 1px #000; box-shadow: none; border-radius: 0; } #page-content .rate-box-with-credit-button .fa-info { border: none; color: #333333; } #page-content .rate-box-with-credit-button .fa-info:hover { background: #333333; color: #ffffff; } .rate-box-with-credit-button .cancel { border: solid 1px #ffffff; } /* ---- PAGE RATING ---- */ .page-rate-widget-box { box-shadow: none; border: solid 1px #000; margin: unset; margin-bottom: 4px; border-radius: 0; } div.page-rate-widget-box .rate-points { background-color: #ffffff; color: #333333; border: none; border-radius: 0; } .page-rate-widget-box .rateup, .page-rate-widget-box .ratedown { background-color: #ffffff; border-top: none; border-bottom: none; } .page-rate-widget-box .rateup a, .page-rate-widget-box .ratedown a { background: transparent; color: #333333; } .page-rate-widget-box .rateup a:hover, .page-rate-widget-box .ratedown a:hover { background: #333333; color: #ffffff; } .page-rate-widget-box .cancel { background: transparent; background-color: #ffffff; border: none; border-radius: 0; } .page-rate-widget-box .cancel a { color: #333333; } .page-rate-widget-box .cancel a:hover { background: #333333; color: #ffffff; border-radius: 0; } #page-content .rate-box-with-credit-button .page-rate-widget-box { border: .anchor { position: sticky; height:0; top: 0; } .sidebox { padding: .14rem; margin-top: 0; margin-bottom: 8px; width: calc((100vw - 870px)/2); max-height: calc(100vh - 18rem); position: absolute; top: 0; left: 103.5%; z-index: 5; overflow: auto; box-sizing: border-box; } @media (max-width: 1290px) { .sidebox { display: none; visibility: hidden; } #header h2::before { font-size: 0.9em !important; } } .scp-image-block { box-shadow: none; } /* ---- YUI TAB BASE ---- */ .yui-navset .yui-nav a,.yui-navset .yui-navset-top .yui-nav a{background-c /* ---- YUI TAB CUSTOMIZATION ----*/ .yui-navset .yui-nav, .yui-navset .yui-navset-top .yui-nav{ display: flex; flex-wrap: wrap; width: calc(100% - .125rem); margin: 0 auto; border-color: #333333; box-shadow: none; } .yui-navset .yui-nav a, /* ---- Link Modifier ---- */ .yui-navset .yui-navset-top .yui-nav a{ color: #333333; /* ---- Tab Background Colour | [UNSELECTED] ---- */ background-color: #efefef; border: unset; box-shadow: none; box-shadow: none; } .yui-navset .yui-nav a:hover, .yui-navset .yui-nav a:focus{ color: #ffffff; /* ---- Tab Background Colour | [HOVER] ---- */ background-color: #333333; } .yui-navset .yui-nav li, /* ---- Listitem Modifier ---- */ .yui-navset .yui-navset-top .yui-nav li{ position: relative; display: flex; flex-grow: 2; max-width: 100%; margin: 0; padding: 0; color: #ffffff; background-color: #ffffff; border-color: transparent; box-shadow: none; } .yui-navset .yui-nav li a, .yui-navset-top .yui-nav li a, .yui-navset-bottom .yui-nav li a{ display: flex; align-items: center; justify-content: center; width: 100%; } .yui-navset .yui-nav li em{ border: unset; } .yui-navset .yui-nav a em, .yui-navset .yui-navset-top .yui-nav a em{ padding: .35em .75em; text-overflow: ellipsis; overflow: hidden; white-space: nowrap; } .yui-navset .yui-nav .selected, /* ---- Selection Modifier ---- */ .yui-navset .yui-navset-top .yui-nav .selected{ flex-grow: 2; margin: 0; padding: 0; /* ---- Tab Background Colour | [SELECTED] ---- */ background-color: #333333; } .yui-navset .yui-nav .selected a, .yui-navset .yui-nav .selected a em{ border: none; } .yui-navset .yui-nav .selected a{ width: 100%; color: #ffffff; } .yui-navset .yui-nav .selected a:focus, .yui-navset .yui-nav .selected a:active{ color: #ffffff; background-color: #333333; } .yui-navset .yui-content { background-color: #ffffff; box-shadow: none; } .yui-navset .yui-content, .yui-navset .yui-navset-top .yui-content{ padding: .5em; border: 1px solid #333; box-sizing: border-box; } /*---- SCROLLBAR ----*/ ::-webkit-scrollbar { width: 10px; } ::-webkit-scrollbar-track { background: #FFF; border-left: 1px solid #333; } ::-webkit-scrollbar-thumb { background: #CCC; border: #333 1px solid; } ::-webkit-scrollbar-thumb:hover { background: #EEE; } /*---- CENTER IMAGES ON MOBILE courtesy of EstrellaYoshte and PeppersGhost .imagediv { float: right; margin: 15px } @media (max-width: 540px) { .imagediv { float: none; text-align:center; margin: auto; } } @media only screen and (max-width: 600px) { .scp-image-block.block-right{ float: none; margin: 10px auto; } } /*---- ACS-COLORED TABLE DIVS ----*/ #page-content .table1 tr th, #page-content .table1 .scp-image-block .scp-image-caption { background-color: #D7EFE7; } #page-content .table2 tr th, #page-content .table2 .scp-image-block .scp-image-caption { background-color: #D8ECF4; } #page-content .table3 tr th, #page-content .table3 .scp-image-block .scp-image-caption { background-color: #FDF6D7; } #page-content .table4 tr th, #page-content .table4 .scp-image-block .scp-image-caption { background-color: #FFDABF; } #page-content .table5 tr th, #page-content .table5 .scp-image-block .scp-image-caption { background-color: #F5D8E0; } #page-content .table6 tr th, #page-content .table6 .scp-image-block .scp-image-caption { background-color: rgba(146, 0, 255, 0.2); } .tableb .wiki-content-table { border-collapse: separate; border-spacing: 2px; } .tableb .scp-image-block { border: none; } .tableb .scp-image-block img { border: #000 1px solid; box-sizing: border-box; } .tableb .scp-image-block .scp-image-caption { margin-top: 2px; border: #000 1px solid; box-sizing: border-box; } .top-left-box > .item { display: none; } /* ---- WORDS NO LONGER BROKEN, THE CROQUEMBOUCHE HAS SPOKEN ---- */ span, a { word-break: normal !important } .avatar-hover { display: none !important; } #breadcrumbs, .pseudocrumbs { text-align: center; padding-top: 10px; } #main-content .page-tags span { max-width: 100%; } /* -- FANCY THINGS from Woedenaz's Dustjacket Theme -- */ .fancyhr hr { border-top: 2vw solid transparent; background-color: rgba(var(--bright-accent), 0); height: 0; box-sizing: border-box; border-image-source: url('https://scp-wiki.wdfiles.com/local--files/th border-image-repeat: round round; background: none; border-image-slice: 80 500 80 500 fill; border-image-width: 10em 80em 10em 80em; } .fancyborder { box-sizing: border-box; border: 2vw solid rgba(0,0,0,0.5); border-image: url('https://scp-wiki.wdfiles.com/local--files/theme%3Af border-image-width: 6; padding: 2vw; } rating: +68+–x Item#: SCP-6763 Level4 Containment Class: esoteric Secondary Class: eparch Disruption Class: vlam Risk Class: danger link to memo CONTAINMENT PROTOCOL: Personnel assigned to the Surrealistics Department, the Antimemetics Division, and the Department of Unreality are to be monitored for inconsistencies in temperament. If any members of staff display signs of persistent anxiety, they are to be granted counselling. In order to maintain current working capacity, resigning employees are to be immediately replaced.
Due to the outflow of staff in these jurisdictions, all funding aimed towards the three departments is to be redirected towards the maintenance and containment of already established and studied department-specific anomalies. Assets and funding intended for independent departmental research and investigative operations are to be frozen for the foreseeable future.
Pending the approval of their assigned therapists, members of staff are allowed Class-C targeted amnestic treatment at request.. Eparch-class anomalies are non-anomalous in nature but relate to anomalous or potentially anomalous phenomena.
DESCRIPTION: SCP-6763 is a series of correlated phenomenon currently affecting members of staff within the Foundation's Surrealistics Department, the Antimemetics Division, and the Department of Unreality. Though SCP-6763's exact parameters are not fully understood, it is believed to involve a mass exodus of Foundation employees from all three departments.. As of 19 July 2025, the Surrealistics Department is at 38% capacity, the Antimemetics Division is at 20%, and the Department of Unreality's capacity is inconclusive. The motives behind these resignations are unclear, with most members of staff being vague in their descriptions and reasoning behind their departures.
Psychologists stationed within Site- ,. Is this even possible? Site-41, and Site-0. No, it isn't. reported increasing levels of stress within collective staff, data which positively correlates with the rapidly increasing rate of staff resignations from the previously stated departments.
SCP-6763-1 is the high likelihood that individuals participating in the mass exodus from the stated departments will develop acute agoraphobia in regards to open spaces.
ADDENDUM 6763.1: Staff Interviews + Sequitur, Marcel: Head of Surrealistics Dept.
Department Head Marcel Sequitur enters the room. He is visibly apprehensive as he crosses the threshold of the open doorway.
Dir. Masonet: Dr. Sequitur, thank you for attending. I understand you're quite a busy man in your line of work, and appreciate you giving us your time today.
Director Masonet stands, reaching out to shake Sequitur's hand. Sequitur concedes.
Sequitur: I do understand, but is this truly necessary?
Dir. Masonet: I'm afraid so.
Director Masonet seats himself on the opposite side of the interviewing table.
Dir. Masonet: The Foundation recognizes the rather unusual yet necessary tactics of your department, and when we picked up on this trend, we became rather concerned over its quite rapid acceleration.
Sequitur: Well, I wouldn't say that there's much to be worried about; we all drop eventually - we are flies after all, borne and spawned and swarming before we turn ourselves inside-out into the ground beneath our feet.
Dir. Masonet: Yes, yes, how very true that is.
There is a pause.
Dir. Masonet: Dr. Sequitur, I wanted to highlight this attendance discrepancy with you. You must already know about it, especially since those that enter Site… Site… Sequitur: Site- .
Dir. Masonet: Thank you, I don't believe I've taken the agnostics required to properly pronounce it. Now, I was… yes - you must already be aware of staff attendance discrepancies, especially since employees under your jurisdiction and Site are the only individuals explicitly willing to engage with such cognitive patterns, this combined with how you and your employees are the only ones able to feasibly enter and exit the facility.
Sequitur: Well, of course - I was very much aware of this. I would like to say that it began with Ms. Noa, but if I try to recall it, it appears more like Mr.
Guiomar. One of them - or both - were talking about potentially detatching from the main mass to pursue alternative psychoscientific routes, ones that could be considered "safer." I remember sitting them at my desk and trying to calm their anxieties, but Noa or Guiomar told me that they didn't feel so comfortable anymore, working on the precipice of a bisected plane. I tried telling them that we were truly at the peak of this new engagement, what with the new Site Director, but they… I didn't fully grasp their intentions until later.
Dir. Masonet: Their intentions, Dr. Sequitir?
Sequitur: Oh, Director, it's out of fear. They're afraid.
Dir. Masonet: What could they be afraid of?
Squitur: It's not… It's not like that, I would say, instead it's more… It isn't something that falls under our sphere of influence, and we'd rather not talk about it in-depth due to it not being under our sphere of influence.
Dir. Masonet: Ok… Director Masonet pinches the bridge of his nose.
Dir. Masonet: Well, if it's potentially memetic, I understand your precaution.
We will just have to do more analysis.
Sequitur: Thank you.
Dir. Masonet: One last thing; Dr. Sequitur, how come your employee registry appears to be gaining staff despite registry plummetting?
Sequitur: It's standard practice that on their way out, before they cast away their badges and chitter'd teeth and hurl themselves into the endward chasm, they replace their names with the names written in their throats, regarding dead memories or forgotten dreams or childhood nostalgia. These lies help keep the positions filled, though temporary, until they as employees are replaced with the standard requirements required to fulfill the job. We haven't actually been departing from Site- , though - we find that semantic associations tend to ricochet quite unhealthily and quite obtuse if depressurizing precautions are not met.
Sequitur lets out a forced, nervous laugh.
Dir. Masonet: Marcel.
Sequitur: Yes, Director?
Dir. Masonet: Why are your people afraid?
Sequitur: Well… If I must be honest, it's because we feel safer in there than out here.
+ Heath, Lilian: Chief Head of Anitmemetics Div.
The Antimemetics Division's chief, Lilian Heath, enters the room. She appears worn-out. There are prominent dark circles underneath her eyelids.
Dir. Masonet: Ms. Heath, thank you for arriving on short notice.
Director Masonet stands to shake her hand.
Heath sighs and reciprocates.
Heath: Well, when the Foundation calls, you have to answer for something.
Heath sits down, almost slumping into her chair. Director Masonet seats himself as well.
Dir. Masonet: We understand that your department is under a great amount of stress; for the record, how long have you been in your position?
Heath: I was assigned chief head of the Antimemetics Division on the 3rd of September, 2023.
Dir. Masonet: And when was your department formed?
Heath: 28th of July, 2023.
Dir. Masonet: Fledglings, really.
Heath: Well, we needed something to investigate them, didn't we?
Dir. Masonet: Of course, of course… now, Ms. Heath, how many members of staff were under your wing at the beginning of the department's formation?
Heath pauses, her gaze drifting up towards the ceiling.
Dir. Masonet: Ms. Heath?
Heath's expression falters for a moment, a quick flash of anxiety crossing her face.
Dir. Masonet: Ms. Heath, I don't want to as- Heath focuses, turning back to Director Masonet. Her expression shifts, hiding the momentary flash of fear.
Heath: Yes, yes, I'm sorry… uh… I don't think… I haven't fully acclimated to mnestic treatment yet. Where were we?
Dir. Masonet: I was just asking you ab- Heath: About staff numbers, yes… Well, off the top of my head, we had about 200 members? It was mostly Level 2 and 3 researchers, nothing too out there. Then, after about a year, we uncovered the remains of several mass-forgotten events, leading to more funding and more assigned staff. So that would make it that by early 2025, we had around… 1500 members? And it was growing.
Dir. Masonet: And the drop?
Heath: That… that occurred around… I'd like to say this past April. It kind of cascaded without anyone fully realizing. It didn't really concern me until some of my best researchers essentially fled the premises. All that they did to notify me was basically sending one-sentence reassignment emails before running to Employee Logistics. It was fast - is fast. I think some of them even quit mnestics cold turkey.
Dir. Masonet: Did they give any reasoning whatsoever into why they resigned?
Heath: Well, we all were aware of something within the division - we had started a new trial of experimental mnestics, and they were working pretty well but their side effects were mostly inconclusive.
Dir. Masonet: How so?
Heath: Extensive use resulted in rising levels of anxiety, sometimes resulting in panic attacks.
Dir. Masonet: Did any of your employees mention what happened during those panic attacks?
Heath: Somewhat - they would feel a sense of vertigo followed by the drug's actual effects kicking in. Though, throughout its influence, they kept reporting that something felt wrong. Nobody could accurately put it into words, though.
Dir. Masonet: Ms. Heath, did you participate in these tests?
Heath's shoulders tensen.
Heath: Of course I did. They're my employees, and they're mine to protect.
Dir. Masonet: Are there any side effects that you can tell us right now?
Anything of note?
Heath hesitates.
Heath: If I listen carefully, I can hear something. It's faint, but it's there. Like hearing an air raid siren from miles away.
Dir. Masonet: Can you elaborate?
Heath: No, I don't think I can.
+ Thorley, Alex: Reality Liaison to Unreality Dept.
Researcher Alex Thorley does not enter the interviewing room. They have no need to enter the interviewing room, because they are already inside.
Director Masonet, caught off-guard, momentarily struggles to stand.
Dir. Masonet: Mx. Thorley! I didn't - I, uh, I wasn't expecting you to be so punctual.
Thorley: It happens. It just happens more often in my line of work.
Dir. Masonet: Yes, it appears so. In regards to your department, I - Thorley: I know. You won't be able to really wrap your head around it, but yes. There's somehow less.
Dir. Masonet: Excuse me? "Less?" Thorley: Yeah. There's less. Department files are completely wiping themselves clean, and not in the usual sense. Entire files of empty, hidden, valuable data just - They reach their hand out in front of them in a large, sweeping motion.
Thorley: Gone.
Dir. Masonet: And you believe that this is because…?
Thorley: I'm not sure. My office is inactive, though. The door just leads to a blank wall now.
Dir. Masonet: If you require assistance in relocating, we'll be more than happy to - Thorley: With all due respect, Director, I am fine, thank you, but there's one last thing I need to bring up.
Dir. Masonet: Go right on ahead.
Thorley: Doe told us that we weren't allowed to look up at the sky.
Thorley abruptly exits. The door remains untouched.
ADDENDUM 6763.2: Internal Pharmaceutical Investigation Site-17's storage facility for Class-A amnestics and Class-W mnestics.
Comparisons of the three departments led to agents discovering that their common vector is the recurrent partaking of differing yet similar Foundation-standard medications in order to facilitate sufficient insight and comprehension in each respective field: agnostics: pharmaceuticals that promote semantic dissociation and non-linear thinking patterns.
mnestics: pharmaceuticals that allow stronger perception, memory recall, and perceptual reinforcement in viewing antimemes.
unmnestics: purpose as-of-yet not fully understood.
This combined with Lilian Heath's testimony led to a thorough investigation on the exact properties of each individual medication. This also lead to the discovery that the upgraded mnestics being tested by the Antimemetics Division were not approved by the Pharmaceutical Department, though they were still unknowingly disseminated amongst sub-departments as the basis for their own various pharmaceutical tools.. The invention of the "mnestic" drug in 1873 lead to a vast expansion of cognitive-altering substances, as doctors and scientists were able to reverse-engineer specific qualities they wanted the drug to enhance. This led to the invention of the first amnestic in 1875, and thus the first agnostic in Anthuary 1226. Even today, mnestics are utilized as the base chemical bedrock for various Foundation-issued cognitive-altering pharmaceuticals.
ADDENDUM 6763.3: Testing The patch of sky that was utilized for the following trials.
Using various optical processing techniques partially adapted from Experiment 3966-10, Foundation scientists were able to construct a cranial apparatus designed to perceive while also transcribing its perceptions, labelling it JONAH.. Repurposed human remains.
While JONAH's transcriptions are rather primitive, they have a 75% accuracy rate when compared to similar predicted snapshot perceptions occurring in the human brain.
Three of these devices were commissioned in order to humanely test the extreme symptoms of the newly-distributed pharmaceuticals.
Trial 1A Protocol: Administer 1 dose of Class-Y altered mnestics into the JONAH device.
STATUS: ONLINE PERCEPTUAL ARRAY: VERIFIED; 89% CAPACITY DESCRIPTION: mute eye floaters floaters floaters white fluffy cloud edge cut sting something spin spin nausea see floaters floaters worm worm harmless QUERY INSERTED: "How do you feel?" DESCRIPTION: sick nausea worm worm looking at up nerves QUERY INSERTED: "Are they working as intended?" • • • DESCRIPTION: worm worm worm worm as intended perception of worm yes. Potentially a reference to various benign antimemetic lifeforms.
DESCRIPTION: else something sky see sky see sky hear see something QUERY INSERTED: "What do you hear?" DESCRIPTION: voice no words voice missing DESCRIPTION: voices DESCRIPTION: i don't like it Trial 1B Protocol: Administer 2 doses of Class-(?) altered unmnestics into the JONAH device STATUS: ONLINE PERCEPTUAL ARRAY: VERIFIED; 92% CAPACITY DESCRIPTION: calm DESCRIPTION: calm QUERY INSERTED: "How do you feel?" DESCRIPTION: calm DESCRIPTION: dangerously so calm QUERY INSERTED: "Can you elaborate?" DESCRIPTION: calm empty means calm means undisturbed which calm means able to parse stillness QUERY INSERTED: "Please elaborate." DESCRIPTION: calm means can sense disturbing in calm QUERY INSERTED: "Something is disturbing your peace?" DESCRIPTION: yes QUERY INSERTED: "What is it?" DESCRIPTION: won't stop DESCRIPTION: constant faraway uncalm DESCRIPTION: 3 3 0 9 3 6 3 9 3 0 5 6 8 5 3 5 3 0 3 6 6 6 5 5 8 9 3 8 0….
JONAH instance kept repeating randomized sequences of 3, 5, 6, 8, 9, and 0 until it was deactivated.
Trial 1C Protocol: Administer 5 doses of base-class altered agnostics into the JONAH device STATUS: IDLE PERCEPTUAL ARRAY: INCOMPLETE; 154% CAPACITY DESCRIPTION: PAIN PAIN INTO UNTO ARLOAN MARCUS REESE BURNING OF THE EARS MIND THEIR THOUGHTS ARE AGONIZING DESCRIPTION: PAIN PAIN PAIN PAIN PAIN PAIN PAIN PAIN QUERY INSERTED: "JONAH, are you alright?" DESCRIPTION: UP UP AROUND ABOUT NET CASTED ON THE SHEER FACE OF COSMOS WOVEN WOVEN WEAVE EVERY THREAD PAIN EVERY THREAD PAIN PAIN PAIN I DO NOT WANT TO LOOK QUERY INSERTED: "JONAH, what are you seeing?" DESCRIPTION: SCREAMING ALL SCREAMING ALL OF IT SCREAMING THE ENTIRE SKY SCREAMING SKY IT IS EVERYWHERE IT BURNS IT BURNS IT BURNS IT BURNS IT BURNS IT BURNS IT BURNS IT BURNS IT. Due to unpredicted excess stimuli, the instance's computing power experienced a surge that destroyed the unit's main processing center.
Data is currently being recovered for study.
This article has been updated. Click to view update.
ADDENDUM 6763.4: 17 August 2025 Update Reclassification to Keter is pending. Drug production in the current quarter is to immediately cease, with current pharmaceuticals being seized by Head Directors.
Amnestic reserves are to be reviewed to remove all contaminated products. Personnel that ingest or participate in contaminated Foundation-issued cognitive-altering substances are not to look at the sky.
Do not talk about what you have seen.
« SCP-6762 | SCP-6763 | SCP-6764 » ‡ Licensing / Citation Cite this page as: "SCP-6763" by Quicksilvers, from the SCP Wiki. Source: https://scpwiki.com/ scp-6763. Licensed under CC-BY-SA.
For information on how to use this component, see the License Box component. To read about licensing policy, see the Licensing Guide.
Filename: pharmacy.jpg Author: Zahid H Javali License: CC 0 Source Link: Link Filename: sky.jpg Author: Stefano Ferrario License: CC 0 Source Link: Link _cc_licenseboxalex-thorleyantimemetics-divisionconceptesoteric-classpattern- screamerscpsurrealistics-deptunreality-dept page revision: 18, last edited: 10 Sep 2024 22:05 Edit Rate (+68) Tags Discuss (10) History Files Print Site tools + Options Edit Sections Append Edit Meta Watchers Backlinks Page Source Parent Lock Page Rename Delete Help  | Terms of Service  | Privacy  | Report a bug  | Flag as objectionable Powered by Wikidot.com Unless otherwise stated, the content of this page is licensed under Creative Commons Attribution-ShareAlike 3.0 License Click here to edit contents of this page.
Click here to toggle editing of individual sections of the page (if possible). Watch headings for an "edit" link when available.
Append content without editing the whole page source.
Check out how this page has evolved in the past.
If you want to discuss contents of this page - this is the easiest way to do it.
View and manage file attachments for this page.
A few useful tools to manage this Site.
See pages that link to and include this page.
Change the name (also URL address, possibly the category) of the page.
View wiki source for this page without editing.
View/set parent page (used for creating breadcrumbs and structured layout).
Notify administrators if there is objectionable content in this page.
Something does not work as expected? Find out what you can do.
General Wikidot.com documentation and help section.
Wikidot.com Terms of Service - what you can, what you should not etc.
Wikidot.com Privacy Policy.
